{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:04:54Z","timestamp":1770447894525,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T00:00:00Z","timestamp":1496016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the 8\u2010year survival of the first tumor necrosis factor inhibitor (TNFi) in patients with axial spondyloarthritis (SpA) or psoriatic arthritis (PsA), identify the predictive factors for withdrawal, and compare the discontinuation rates for infliximab, etanercept, and adalimumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated PsA and axial SpA patients treated with a first\u2010line TNFi between 2005 and 2015 at 4 Italian tertiary centers. Eight\u2010year drug survival was calculated by the Kaplan\u2010Meier method, and risk for discontinuation among treatment groups compared by stratified log\u2010rank test. Univariate and multivariate Cox proportional hazard models were developed to examine predictors of withdrawal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 614 patients (316 axial with SpA, 298 with PsA), 203 received adalimumab, 131 etanercept, and 280 infliximab, with similar frequencies in axial SpA and PsA subgroups. The cumulative 8\u2010year retention rate in the whole population was 55.1% (57.2% and 51.9% for axial SpA and PsA, respectively; <jats:italic>P<\/jats:italic>\u2009=\u2009not significant). No significant differences were observed in drug persistence among individual TNFi in either group. Male sex (hazard ratio [HR] 0.595 [95% confidence interval (95% CI) 0.405\u20130.875]; <jats:italic>P<\/jats:italic>\u2009=\u20090.008) and concomitant methotrexate use (HR 0.648 [95% CI 0.426\u20130.985]; <jats:italic>P<\/jats:italic>\u2009=\u20090.042) were associated with a lower risk of withdrawal in PsA. High baseline Bath Ankylosing Spondylitis Disease Activity Index (HR 0.9842 [95% CI 0.9708\u20130.9980]; <jats:italic>P<\/jats:italic>\u2009=\u20090.028) was associated with a lower risk of withdrawal in axial SpA. No difference was found in the comparative analysis of reasons for discontinuation between PsA and axial SpA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We reported that the real\u2010life 8\u2010year retention rate of the first TNFi in axial SpA and PsA is greater than 50%, with no significant differences between axial SpA and PsA, irrespective of the individual TNFi.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.23090","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T09:00:24Z","timestamp":1475830824000},"page":"867-874","source":"Crossref","is-referenced-by-count":36,"title":["Eight\u2010Year Retention Rate of First\u2010Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis"],"prefix":"10.1002","volume":"69","author":[{"given":"Ennio Giulio","family":"Favalli","sequence":"first","affiliation":[{"name":"Gaetano Pini Institute Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[{"name":"Humanitas Research Hospital, Rozzano, and University of Milan Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Becciolini","sequence":"additional","affiliation":[{"name":"Gaetano Pini Institute Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Biggioggero","sequence":"additional","affiliation":[{"name":"University of Milan and Gaetano Pini Institute Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alarico","family":"Ariani","sequence":"additional","affiliation":[{"name":"University Hospital Parma Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Santilli","sequence":"additional","affiliation":[{"name":"University Hospital Parma Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Fusaro","sequence":"additional","affiliation":[{"name":"Citt\u00e0 Della Salute e della Scienza Turin Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Parisi","sequence":"additional","affiliation":[{"name":"Citt\u00e0 Della Salute e della Scienza Turin Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Massarotti","sequence":"additional","affiliation":[{"name":"Humanitas Research Hospital Rozzano Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[{"name":"Gaetano Pini Institute Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Meroni","sequence":"additional","affiliation":[{"name":"University of Milan and IRCCS Istituto Auxologico Italiano Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes026"},{"key":"e_1_2_6_4_1","first-page":"CD005468","article-title":"TNF\u2010alpha inhibitors for ankylosing spondylitis","volume":"4","author":"Maxwell LJ","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.028530"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.11.003"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124446"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30117"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2670"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1941"},{"key":"e_1_2_6_12_1","first-page":"857","article-title":"Drug survival of the first course of anti\u2010TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database","volume":"31","author":"Scir\u00e8 CA","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2014.962081"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23333"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062760"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq242"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.06.011"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22788"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2016.1147954"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1890-3"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201357"},{"key":"e_1_2_6_22_1","first-page":"419","article-title":"Gender\u2010attributable differences in outcome of ankylosing spondylitis: long\u2010term results from the Outcome in Ankylosing Spondylitis International Study","volume":"55","author":"Webers C","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202347"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206616"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04621.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111125"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23090","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.23090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:27:47Z","timestamp":1759418867000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.23090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,29]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1002\/acr.23090"],"URL":"https:\/\/doi.org\/10.1002\/acr.23090","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,29]]}}}